Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the ...

Gain Therapeutics (GANX) provided a letter to shareholders from the Company’s President and CEO, Gene Mack, which read in part,”With 2025 ...

The typical idiopathic PD patient presents with asymmetrical ... The Core Assessment Program for Surgical Interventional Therapies in Parkinson's disease recommends that a battery of cognitive ...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports.

The condition is characterised by shoulder joint inflammation, often without a clear cause, beginning with pain and stiffness that leads to significant immobility.

[24] The cognitive impairment observed in INPH has some similarity to other subcortical dementias, including Parkinson's disease ... Hydrocephalus Association. Idiopathic normal pressure ...

Learn more about whether AbbVie Inc. or Genmab A/S is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report)‘s stock had its “buy” rating restated by D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have ...